Coegin Pharma (NGM:COEGIN) Short Percentage of Float


NGM:COEGIN Coegin Pharma NGM:COEGIN
29 GF Score
Price kr3.69
! 2 Warning Signs
View Full Analysis

What is Coegin Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NGM:COEGIN vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Coegin Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coegin Pharma Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coegin Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Coegin Pharma's Short Percentage of Float falls into.


NGM:COEGIN
29GF Score
Coegin Pharma NGM:COEGIN
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coegin Pharma Business Description

Other Exchanges 7Z6:Germany
Address c/o Medicon Village, Lund, SWE, 223 81
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score

Get the complete analysis for NGM:COEGIN

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.69
Price